SCHEMBL1406844

SCHEMBL1406844

CCN(CC)c1ccc(-c2cc(C(=O)/C=C/c3ccc(C(=O)O)c(O)c3)cc3c2C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.43
MAPK1 P28482 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 3/20 0.40
MAPT P10636 3/20 0.40
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40
TLR9 Q9NR96 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
RXRA P19793 6/20 0.39
RXRB P28702 5/20 0.39
RXRG P48443 5/20 0.39
NPSR1 Q6W5P4 1/20 0.38
FGFR1 P11362 1/20 0.38
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406845 1.00 MAOB (0.43) MAOBMAPK1MEN1KMT2AL3MBTL1
SCHEMBL1406426 0.91 MAOB (0.46) MAOBMAPK1MEN1KMT2AL3MBTL1
SCHEMBL1406425 0.91 MAOB (0.46) MAOBMAPK1MEN1KMT2AL3MBTL1
SCHEMBL1406386 0.89 MAPK1 (0.48) MAPK1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1406383 0.89 MAPK1 (0.48) MAPK1MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1406563 0.88 RXRA (0.45) MAOBKMT2AALDH1A1MAPTRXRA
SCHEMBL1406565 0.88 RXRA (0.45) MAOBKMT2AALDH1A1MAPTRXRA
SCHEMBL1406663 0.86 APP (0.48) MAOBMAPK1MEN1KMT2AL3MBTL1
SCHEMBL1406660 0.86 APP (0.48) MAOBMAPK1MEN1KMT2AL3MBTL1
SCHEMBL1406830 0.85 TP53 (0.41) MAPK1ALDH1A1POLBMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG MAOB 1897/4885MAPK1 2843/4885MEN1 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.